This is unpublished
MEMO
Active Studies
Transplantation
Pinned
Principal Investigator
Nicolae Leca, MD
Funding Agency
Sponsor: MEMO Therapeutics AG
Status
Active
Enrollment closed
Investigator
What is the memo Study?
Safety, tolerability and efficacy of AntiBKV as treatment of BKV infection in kidney transplant recipients, a randomized phase II/III study, double-blind and placebo-controlled -- To assess whether treatment with AntiBKV decreases BKV DNAemia to undetectable at Day 141 in KTRs with BKV DNAemia
What are the criteria for the study?
Male or female aged 18 years or older; kidney transplant recipient with first-time BKV DNAemia defined as BKV DNAemia of one time greater than 10,000 copies/mL or greater than 1,000 copies/mL sustained for at least one week.
WHO DO I CONTACT FOR MORE INFORMATION?
Research Coordinator
Belinda Pan
E: bcpan@uw.edu